Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Condition·Updated Jul 11, 2026·v1

Marfan Syndrome

Marfan syndrome is an autosomal dominant connective tissue disorder caused by FBN1 mutations, leading to TGF-β dysregulation and progressive aortic root dilation, ectopia lentis, and skeletal abnormalities. The diagnosis relies on the revised Ghent criteria. Management centers on lifelong beta-blocker therapy, ARB add-on, strict blood pressure control, and prophylactic aortic root replacement at ≥50 mm (or ≥45 mm with risk factors). Annual imaging surveillance is essential. Special considerations include pregnancy, pediatric care, and avoidance of fluoroquinolones and heavy isometric exercise.

High Evidence157 references·2,379 words·10 min read·v1
Marfan syndromeFBN1aortic dissectionconnective tissue disorderectopia lentisGhent criteriabeta-blockerangiotensin receptor blockervalve-sparing root replacement

Quick Reference

RxDrug of choiceBeta-blocker (atenolol 25-100 mg daily) for first-line aortic root protection in all patients with aortic dilation
AltAlternativesAngiotensin receptor blocker (losartan 25-100 mg daily or irbesartan 75-300 mg daily) as adjunct or alternative to beta-blocker
⊘AvoidFluoroquinolones (increased dissection risk), ARBs in second/third trimester of pregnancy, non-dihydropyridine CCBs (diltiazem, verapamil) are relatively contraindicated in heart failure but not specifically in Marfan
DxTest of choiceTransthoracic echocardiography with aortic root z-score measurement (first-line); CMR/CTA for entire aorta at baseline and during follow-up
ScKey scoreRevised Ghent systemic score (≥7 points supports diagnosis when combined with aortic root disease or FBN1 mutation)
→When to referAortic root diameter ≥50 mm (or ≥45 mm with rapid growth >2 mm/year, family history of dissection, severe aortic regurgitation); acute aortic dissection; rapid aortic dilation; pregnancy planning with aortic root >4.0 cm
Marfan syndrome requires lifelong beta-blocker therapy, addition of an ARB for enhanced aortic protection, annual echocardiographic surveillance, and prophylactic aortic root replacement at 50 mm to prevent catastrophic dissection.
Marfan syndrome (MFS) is an autosomal dominant, multisystem connective tissue disorder caused by pathogenic variants in the FBN1 gene, encoding fibrillin-1, which regulates TGF-β bioavailability [8][9][27]. Life-threatening aortic root dilatation and dissection are the predominant causes of reduced life expectancy [8][18]. This concise reference covers diagnosis, risk stratification, medical and surgical management, and special population considerations.

Overview and Recommendations

Background

  • •Marfan syndrome is an autosomal dominant connective tissue disorder caused by pathogenic variants in , the gene encoding fibrillin-1, leading to dysregulated signaling that drives progressive aortic root dilation and multisystem manifestations spanning skeletal, ocular, cardiovascular, and pulmonary systems.
  • •With an estimated prevalence of 1 in 5,000 to 1 in 10,000, Marfan syndrome carries a high morbidity and mortality primarily from aortic root aneurysm and dissection, the annual risk of dissection rises from 0.09% at aortic diameters <40 mm to 1.33% at 50-54 mm.
  • •The 2010 revised Ghent criteria establish the diagnosis using two major scenarios: aortic root dilation (z-score ≥2) or dissection plus ectopia lentis; or aortic root disease plus a pathogenic variant, with a systemic score ≥7 points providing additional diagnostic support.
  • •Cardiovascular involvement is the leading cause of death and includes , with (present in ~34% of patients), and a primary cardiomyopathy independent of valvular disease.
  • •Prophylactic aortic root replacement at ≥50 mm (or ≥45 mm with rapid growth >2 mm/year, family history of dissection, or severe aortic regurgitation) is the cornerstone of prevention; valve-sparing root replacement (David procedure) is the preferred elective technique.
  • •Approximately 25% of cases are de novo mutations, and men carry a higher aortic risk (HR 1.4 for aortic events). Family history of dissection is the strongest risk factor (RR 6.82).

Evaluation

  • •Suspect Marfan syndrome in any young patient presenting with aortic dissection, ectopia lentis, spontaneous pneumothorax, or unexplained tall stature with arachnodactyly and joint hypermobility.
  • •Ask about family history of aortic dissection, sudden cardiac death, or known connective tissue disorders, first-degree relatives of an affected proband have a relative risk of 6.82 for aortic dissection.
  • •Ask about ocular symptoms: blurred vision from lens subluxation (ectopia lentis, typically superotemporal), myopia, or history of retinal detachment; these are often presenting complaints.
  • •Ask about skeletal symptoms: joint hypermobility, scoliosis, pectus deformity (excavatum or carinatum), flat feet, and prior spontaneous pneumothorax.
  • •Examine for the wrist sign (overlap of thumb and little finger around the opposite wrist) and thumb sign (thumb protrudes beyond ulnar border when hand is clenched), both together score 3 points on the Ghent systemic score.
  • •Examine for pectus carinatum (2 points), pectus excavatum (1 point), hindfoot valgus (2 points), pes planus (1 point), scoliosis ≥20° (1 point), reduced elbow extension ≤170° (1 point), and characteristic facial features: dolichocephaly, enophthalmos, downslanting palpebral fissures, malar hypoplasia, retrognathia (1 point if 3 of 5 present).
  • •Auscultate for a mid-systolic click (mitral valve prolapse, 1 point) and a diastolic murmur (aortic regurgitation). Note that is present in >60% and may cause low back pain or radicular symptoms.
  • •Order as first-line imaging: measure aortic root diameter at the sinuses of Valsalva in end-diastole, leading edge to leading edge, and calculate a z-score adjusted for age and body surface area (z-score ≥2 is abnormal; absolute ≥40 mm is dilated in adults).
  • •Order cardiac magnetic resonance or computed tomography angiography of the entire aorta at baseline to assess beyond the root: check for (VTI ≥50 predicts earlier dissection), aortic branch aneurysms (present in 27% and independently predict need for surgery, HR 3.4), and dural ectasia.
  • •Apply the revised Ghent criteria: if the patient has aortic root dilation/dissection plus ectopia lentis, the diagnosis is established regardless of genetic testing. If aortic root disease is present without ectopia lentis, a pathogenic mutation or a systemic score ≥7 is required.
  • •Order genetic testing (targeted next-generation sequencing) to confirm the diagnosis and inform genotype-phenotype correlations: variants confer higher aortic risk (HR 2.5 for cardiovascular death) and a 60% incidence of pregnancy-related dissection.
  • •If FBN1 testing is negative but clinical suspicion remains high, order a multigene panel for heritable thoracic aortic disease including , , , , and to rule out Loeys-Dietz syndrome and vascular Ehlers-Danlos syndrome.
  • •Also consider differential diagnoses: (bifid uvula, hypertelorism, arterial tortuosity, dissection at smaller diameters), (easy bruising, thin skin, visceral rupture), familial thoracic aortic aneurysm syndrome (isolated aortic dilation, no systemic features), and MASS phenotype (myopia, MVP, borderline aortic root, no ectopia lentis, no dissection).
  • •Screen all first-degree relatives with echocardiography and genetic counseling if the proband has a confirmed pathogenic FBN1 variant or meets Ghent criteria clinically.
  • •In children, use aortic z-scores against published normative data; annual echo is standard, with more frequent imaging (every 6 months) if z-score >3 or rapid dilation is detected.

Management

  • •For acute aortic dissection, immediately administer IV (esmolol 250-500 μg/kg loading dose then 50-200 μg/kg/min, or labetalol 10-20 mg IV every 10 minutes) to achieve heart rate <60 bpm and systolic BP 100-120 mm Hg; add IV vasodilator (nicardipine 5 mg/h or clevidipine 1-2 mg/h) only after beta-blockade is established, monotherapy with vasodilator is dangerous due to reflex tachycardia.
  • •For type A aortic dissection, perform emergency complete aortic root replacement: (David reimplantation) is preferred over supracoronary ascending replacement alone, which has a 40% reintervention rate at 20 years. If valve is irreparable, use a mechanical composite graft.
  • •For uncomplicated type B dissection, medical management with beta-blockade and aggressive BP control is first-line, but given the high progression rate in Marfan (68% require late surgery), immediate multidisciplinary aortic team consultation is recommended; complicated type B (malperfusion, rupture, refractory pain, rapid expansion) requires urgent TEVAR or open repair.
  • •Initiate long-term therapy as first-line for all patients with aortic root dilation: start 25 mg once daily and titrate to 50-100 mg daily (target resting heart rate 60-70 bpm, blood pressure <130/80 mm Hg). In children, weight-based dosing is used.
  • •Add an as adjunctive therapy: start 25-50 mg once daily, titrate to 100 mg daily (50 mg if weight <50 kg); alternatively 75 mg once daily, increase to 150-300 mg daily. ARBs reduce the annual rate of aortic root Z-score change by approximately 50% (Class IIa recommendation).
  • •Monitor blood pressure, serum potassium, and renal function when initiating or titrating ARBs; avoid ARBs during pregnancy (second and third trimesters) due to fetotoxicity.
  • •Perform annual transthoracic echocardiography to measure aortic root diameter; if stable for 2 years, consider extending interval to every 2 years. In children or those with rapid progression, image every 6 months.
  • •Refer for prophylactic aortic root replacement when the aortic diameter reaches ≥50 mm (or ≥45 mm with rapid growth >2 mm/year, family history of dissection, or severe ). Valve-sparing root replacement (David technique) is the preferred elective procedure.
  • •Avoid in Marfan patients, they are associated with an increased risk of aortic dissection and should only be used if no alternative exists.
  • •Avoid strenuous isometric exercise and heavy weightlifting; encourage moderate aerobic activity (walking, swimming, cycling). A personalized home-based exercise program can improve aerobic capacity without affecting aortic diameter.
  • •In pregnancy, continue beta-blocker therapy throughout gestation, the maternal survival benefit outweighs the small risk of fetal growth restriction (mean 442 g lower birth weight). Monitor aortic root with echocardiography every 4-8 weeks.
  • •Consider delivery by if the aortic root diameter exceeds 4.0 cm or if rapid dilation occurs; vaginal delivery with epidural anesthesia and a shortened second stage is an option for women with root <4.0 cm and stable dimensions.
  • •Postpartum surveillance is critical: 2.7% of women experience dissection during postpartum hospitalization and 2.7% are re-hospitalized for dissection within one year; continue beta-blocker and image at 3, 6, and 12 months postpartum.
  • •In children, initiate beta-blocker (atenolol or nadolol) as first-line; add if aortic dilation progresses. Annual echo with z-score monitoring; restrict competitive sports with high static/isometric demands, but encourage moderate aerobic activity.
  • •Screen for (MAD >10 mm) on echocardiography, these patients have higher rates of aortic events (60% vs 21%) and ventricular arrhythmias, warranting Holter monitoring and low threshold for electrophysiology consultation.
  • •Redo sternotomy is common (41% of operated patients): optimize blood pressure control (hypertension OR 2.39) and plan with a multidisciplinary aortic team. After initial root replacement, lifelong surveillance of the entire aorta is required because new distal dissection occurs in 16.5% at 15 years.
  • •What NOT to do: do not treat the ascending aorta using thresholds derived from bicuspid aortic valve disease (Marfan patients face higher dissection risk); do not prescribe ARBs in pregnancy; do not use vasodilators before beta-blockers in acute aortic syndrome; do not recommend heavy weightlifting or contact sports.
  • •Discharge criteria after acute dissection: stable hemodynamics, controlled BP and heart rate on oral therapy, postoperative CTA documenting residual dissection, and a clear plan for follow-up imaging at 3, 6, and 12 months, then annually.

Board Review — High Yield

  • •FBN1 mutation, causes Marfan syndrome via deficient fibrillin-1 and dysregulated TGF-β signaling, leading to aortic root aneurysm, ectopia lentis, and skeletal abnormalities.
  • •Revised Ghent criteria, diagnosis requires aortic root dilation (z-score ≥2) or dissection plus ectopia lentis, OR aortic root disease plus FBN1 mutation or systemic score ≥7 (points from skeletal, ocular, cardiovascular, skin features).
  • •Aortic dissection risk, annual risk rises from 0.09% at <40 mm to 1.33% at 50-54 mm; prophylactic root replacement at ≥50 mm (or ≥45 mm with risk factors) is the standard.
  • •Beta-blocker first-line, atenolol or propranolol targeting HR 60-70 bpm to reduce aortic wall stress and slow root dilation.
  • •ARB therapy, losartan or irbesartan reduces aortic root dilation rate by ~50% via TGF-β antagonism; can be added to beta-blocker or used as alternative.
  • •Valve-sparing root replacement (David procedure), preferred elective surgery for aortic root aneurysm, offering superior survival and lower reintervention rates compared to composite graft or supracoronary replacement.
  • •Ectopia lentis, lens subluxation (typically superotemporal) is a cardinal ocular feature present in ~60% of patients; highly specific for Marfan syndrome when combined with aortic dilation.
  • •Pregnancy risks, 5-fold increased dissection risk; continue beta-blocker; monitor aortic root every 4-8 weeks; consider C-section if root >4.0 cm; avoid ARBs in second/third trimester.
  • •Mitral annular disjunction >10 mm, present in 34% of patients and associated with higher aortic event rates (60% vs 21%) and ventricular arrhythmias; warrants intensified surveillance and Holter monitoring.
  • •Family screening, all first-degree relatives need echocardiography and genetic counseling; family history of dissection is the strongest risk factor (RR 6.82).

Deep Dive — Evidence Details

References

  1. [1]

    Isselbacher EM, Preventza O, Hamilton Black J et al.. “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” Circulation (2022). PMID: 36322642 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Special Populations and Prevention
  2. [2]

    Isselbacher EM, Preventza O, Hamilton Black Iii J et al.. “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2022). PMID: 36334952 ↗

    L1GUIDELINECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Special Populations and Prevention
  3. [3]

    Teixido-Tura G, Forteza A, Rodríguez-Palomares J et al.. “Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.” Journal of the American College of Cardiology (2018). PMID: 30261963 ↗

    L2RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  4. [4]

    Morris SA, Flyer JN, Yetman AT et al.. “Cardiovascular Management of Aortopathy in Children: A Scientific Statement From the American Heart Association.” Circulation (2024). PMID: 39129620 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  5. [5]

    Fletcher AJ, Syed MBJ, Aitman TJ et al.. “Inherited Thoracic Aortic Disease: New Insights and Translational Targets.” Circulation (2020). PMID: 32392100 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy
  6. [6]

    Goldfinger JZ, Halperin JL, Marin ML et al.. “Thoracic aortic aneurysm and dissection.” Journal of the American College of Cardiology (2014). PMID: 25323262 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  7. [7]

    Mullen M, Jin XY, Child A et al.. “Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.” Lancet (London, England) (2019). PMID: 31836196 ↗

    L1RCTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  8. [8]

    Muiño-Mosquera L, Cervi E, De Groote K et al.. “Management of aortic disease in children with FBN1-related Marfan syndrome.” European heart journal (2024). PMID: 39250726 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  9. [9]

    Matt P, Schoenhoff F, Habashi J et al.. “Circulating transforming growth factor-beta in Marfan syndrome.” Circulation (2009). PMID: 19635970 ↗

    L5OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  10. [10]

    Isselbacher EM, Bonaca MP, Di Eusanio M et al.. “Recurrent Aortic Dissection: Observations From the International Registry of Aortic Dissection.” Circulation (2016). PMID: 27587434 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
  11. [11]

    Attias D, Stheneur C, Roy C et al.. “Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders.” Circulation (2009). PMID: 19996017 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  12. [12]

    Kunkala MR, Schaff HV, Li Z et al.. “Mitral valve disease in patients with Marfan syndrome undergoing aortic root replacement.” Circulation (2013). PMID: 24030414 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy
  13. [13]

    Evangelista A, Salas A, Ribera A et al.. “Long-term outcome of aortic dissection with patent false lumen: predictive role of entry tear size and location.” Circulation (2012). PMID: 22615344 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
  14. [14]

    Calderon-Martinez E, Velasco WV, Guo D et al.. “Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome.” Journal of the American College of Cardiology (2025). PMID: 40533124 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications
  15. [15]

    Lopez-Sainz A, Mila L, Rodriguez-Palomares J et al.. “Aortic Branch Aneurysms and Vascular Risk in Patients With Marfan Syndrome.” Journal of the American College of Cardiology (2021). PMID: 34140103 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  16. [16]

    Narula N, Devereux RB, Malonga GP et al.. “Pregnancy-Related Aortic Complications in Women With Marfan Syndrome.” Journal of the American College of Cardiology (2021). PMID: 34446158 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention
  17. [17]

    Giuliani L, Di Toro A, Urtis M et al.. “Prevalence and Complications of Aberrant Subclavian Artery in Patients With Heritable and Nonheritable Arteriopathies.” Journal of the American College of Cardiology (2023). PMID: 36889877 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications
  18. [18]

    David TE, Park J, Tatangelo M et al.. “Cardiovascular Events After Aortic Root Repair in Patients With Marfan Syndrome.” Journal of the American College of Cardiology (2023). PMID: 37673508 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications
  19. [19]

    Guala A, Teixidó-Tura G, Rodríguez-Palomares J et al.. “Proximal aorta longitudinal strain predicts aortic root dilation rate and aortic events in Marfan syndrome.” European heart journal (2019). PMID: 30977783 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Complications, Prognosis and Natural History
  20. [20]

    Alpendurada F, Wong J, Kiotsekoglou A et al.. “Evidence for Marfan cardiomyopathy.” European journal of heart failure (2010). PMID: 20861133 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment, Complications, Prognosis and Natural History
  21. [21]

    Abdul Nabi H, Dreher LA, Kanaan C et al.. “Cardiac surgical outcomes and predictors of redo sternotomy in patients with Marfan syndrome: a retrospective multicentre cohort study.” Open heart (2026). PMID: 42229999 ↗

    L2COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications
  22. [22]

    Jia WN, Chen ZX, Shen X et al.. “Clinical and Surgical Implications of Genotype-Phenotype Correlations in Congenital Ectopia Lentis: A Real-World Cohort Study.” Investigative ophthalmology & visual science (2026). PMID: 42126156 ↗

    L4COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management
  23. [23]

    Braverman AC, Mittauer E, Harris KM et al.. “Clinical Features and Outcomes of Pregnancy-Related Acute Aortic Dissection.” JAMA cardiology (2021). PMID: 33052376 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention
  24. [24]

    Demolder A, Timmermans F, Duytschaever M et al.. “Association of Mitral Annular Disjunction With Cardiovascular Outcomes Among Patients With Marfan Syndrome.” JAMA cardiology (2021). PMID: 34232254 ↗

    L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications
  25. [25]

    Yang Y, Muzny DM, Xia F et al.. “Molecular findings among patients referred for clinical whole-exome sequencing.” JAMA (2014). PMID: 25326635 ↗

    L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy
  26. [26]

    Chen X, Ryu JH, Hu X. “Spontaneous pneumothorax-associated with genetic disorders.” Therapeutic advances in respiratory disease (2026). PMID: 41905781 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  27. [27]

    Maciel Oliveira G, Junqueira Franco Stoppe J, Duarte de Andrade SM et al.. “What's new about angiotensin receptor blocker (ARB) therapy for Marfan syndrome: A narrative review.” Vascular medicine (London, England) (2026). PMID: 41631533 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Long-term Guideline-Directed Therapy
  28. [28]

    Abdul-Rahman T, Roy P, Garg N et al.. “Gene editing for inherited cardiac conditions: A new frontier in cardiology.” Trends in cardiovascular medicine (2025). PMID: 41237872 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation
  29. [29]

    Jayaratne N, Gianni A, Riding N et al.. “Exercise recommendations for patients with Marfan syndrome: an updated review.” European journal of preventive cardiology (2026). PMID: 41152210 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications, Prognosis and Natural History
  30. [30]

    Autret L, Shipley É, Lodde B et al.. “Rheumatic and musculoskeletal disorders in musicians: risks, adaptations and management.” RMD open (2025). PMID: 41083266 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, History and Evolution of Treatment
  31. [31]

    Vialle R. “Pathologies of the cervical spine in skeletal syndromes and dysplasias.” Orthopaedics & traumatology, surgery & research : OTSR (2025). PMID: 40976314 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Complications
  32. [32]

    Milleron O, Arnoult F, Ropers J et al.. “Marfan Sartan: a randomized, double-blind, placebo-controlled trial.” European heart journal (2015). PMID: 25935877 ↗

    L1RCTCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History
  33. [33]

    Jondeau G, Detaint D, Tubach F et al.. “Aortic event rate in the Marfan population: a cohort study.” Circulation (2011). PMID: 22133496 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History
  34. [34]

    Isselbacher EM, Lino Cardenas CL, Lindsay ME. “Hereditary Influence in Thoracic Aortic Aneurysm and Dissection.” Circulation (2016). PMID: 27297344 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism
  35. [35]

    Raunsø J, Song RJ, Vasan RS et al.. “Familial Clustering of Aortic Size, Aneurysms, and Dissections in the Community.” Circulation (2020). PMID: 32580567 ↗

    L2OTHERCited in: Epidemiology and Risk Factors
  36. [36]

    Rylski B, Bavaria JE, Beyersdorf F et al.. “Type A aortic dissection in Marfan syndrome: extent of initial surgery determines long-term outcome.” Circulation (2014). PMID: 24594630 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Complications, Prognosis and Natural History
  37. [37]

    Schoenhoff FS, Jungi S, Czerny M et al.. “Acute aortic dissection determines the fate of initially untreated aortic segments in Marfan syndrome.” Circulation (2013). PMID: 23493319 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Complications
  38. [38]

    Narula N, Devereux RB, Arbustini E et al.. “Risk of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry.” Journal of the American College of Cardiology (2023). PMID: 37930285 ↗

    L3OTHERCited in: Epidemiology and Risk Factors, History and Evolution of Treatment
  39. [39]

    Milleron O, Arnoult F, Delorme G et al.. “Pathogenic FBN1 Genetic Variation and Aortic Dissection in Patients With Marfan Syndrome.” Journal of the American College of Cardiology (2020). PMID: 32130918 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History
  40. [40]

    David TE, David CM, Manlhiot C et al.. “Outcomes of Aortic Valve-Sparing Operations in Marfan Syndrome.” Journal of the American College of Cardiology (2015). PMID: 26403341 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Interventional and Device Therapy, Prognosis and Natural History
  41. [41]

    Chen SW, Kuo CF, Huang YT et al.. “Association of Family History With Incidence and Outcomes of Aortic Dissection.” Journal of the American College of Cardiology (2020). PMID: 32883411 ↗

    L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment, Prognosis and Natural History
  42. [42]

    Détaint D, Faivre L, Collod-Beroud G et al.. “Cardiovascular manifestations in men and women carrying a FBN1 mutation.” European heart journal (2010). PMID: 20709720 ↗

    L2OTHERCited in: Epidemiology and Risk Factors
  43. [43]

    Henry M, Campello Jorge CA, van Bakel PAJ et al.. “Thoracic Aortic Aneurysm Growth Rates and Predicting Factors: A Systematic Review and Meta-Analysis.” Journal of the American Heart Association (2025). PMID: 40145320 ↗

    L2SR_OBSCited in: Epidemiology and Risk Factors
  44. [44]

    Brown RF, Lopez K, Smith CB et al.. “Diverticulitis: A Review.” JAMA (2025). PMID: 40705318 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Special Populations and Prevention
  45. [45]

    Zhang Y, Lin H, Li Y et al.. “Aortic root replacement versus preservation in acute type A aortic dissection repair: meta-analysis of reconstructed time-to-event data.” Journal of cardiothoracic surgery (2025). PMID: 41353548 ↗

    L2SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Prognosis and Natural History
  46. [46]

    Tanriverdi LH, Barrett A, Kalyanasundaram A et al.. “Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials.” Vascular pharmacology (2025). PMID: 40204023 ↗

    L1SR_MA_RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Prognosis and Natural History
  47. [47]

    Grégori M, Le Gloan L, Goronflot T et al.. “Impact of β-Blockers on the Risk of Low-Birth-Weight Infants in Women with Long QT Syndrome or Marfan Syndrome: A Single-Center Retrospective Study from 2008 to 2022 in a Tertiary Care Center.” Paediatric drugs (2026). PMID: 41653364 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention
  48. [48]

    Shen X, Chen Z, Jia W et al.. “Phenotype-driven clustering of ocular manifestations reveals prognostic and genetic heterogeneity in Marfan syndrome: a real-world longitudinal cohort study.” Journal of translational medicine (2025). PMID: 41331757 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History
  49. [49]

    Bin Helayel H, Magliyah MS, Alnutaifi R et al.. “Surgical Outcomes of Lens Removal with or Without Intraocular Lens Implantation in Marfan Syndrome: A Retrospective Cohort Study.” Clinical ophthalmology (Auckland, N.Z.) (2025). PMID: 41282459 ↗

    L2COHORTCited in: Epidemiology and Risk Factors, Clinical Presentation, Prognosis and Natural History
  50. [50]

    Nagata K, Taniguchi Y, Nakajima K et al.. “Bone mineral density in pediatric Marfan syndrome patients with scoliosis: a retrospective case-control study using hounsfield units.” European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2026). PMID: 41894045 ↗

    L3CASE_CONTROLCited in: Epidemiology and Risk Factors
  51. [51]

    Yetman AT, Graham T. “The dilated aorta in patients with congenital cardiac defects.” Journal of the American College of Cardiology (2009). PMID: 19195601 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  52. [52]

    Hofmann Bowman MA, Eagle KA, Milewicz DM. “Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.” JAMA cardiology (2019). PMID: 31066871 ↗

    L5TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Acute and Initial Management, Complications
  53. [53]

    Oller J, Gabandé-Rodríguez E, Ruiz-Rodríguez MJ et al.. “Extracellular Tuning of Mitochondrial Respiration Leads to Aortic Aneurysm.” Circulation (2021). PMID: 33709773 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy
  54. [54]

    Kim AJ, Xu N, Umeyama K et al.. “Deficiency of Circulating Monocytes Ameliorates the Progression of Myxomatous Valve Degeneration in Marfan Syndrome.” Circulation (2020). PMID: 31928435 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Complications
  55. [55]

    Heegaard AM, Corsi A, Danielsen CC et al.. “Biglycan deficiency causes spontaneous aortic dissection and rupture in mice.” Circulation (2007). PMID: 17502576 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  56. [56]

    Ikonomidis JS, Jones JA, Barbour JR et al.. “Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome.” Circulation (2006). PMID: 16820601 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Acute and Initial Management, Complications
  57. [57]

    Zheng J, Chen Y, Pat B et al.. “Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dog.” Circulation (2009). PMID: 19349319 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation
  58. [58]

    Guo G, Booms P, Halushka M et al.. “Induction of macrophage chemotaxis by aortic extracts of the mgR Marfan mouse model and a GxxPG-containing fibrillin-1 fragment.” Circulation (2006). PMID: 17030689 ↗

    L5OTHERCited in: Pathophysiology and Mechanism
  59. [59]

    Geirsson A, Singh M, Ali R et al.. “Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers.” Circulation (2012). PMID: 22965982 ↗

    L3OTHERCited in: Pathophysiology and Mechanism
  60. [60]

    Roberts WC, Vowels TJ, Ko JM et al.. “Comparison of the structure of the aortic valve and ascending aorta in adults having aortic valve replacement for aortic stenosis versus for pure aortic regurgitation and resection of the ascending aorta for aneurysm.” Circulation (2011). PMID: 21321157 ↗

    L4OTHERCited in: Pathophysiology and Mechanism
  61. [61]

    Roberts WC, Ko JM, Moore TR et al.. “Causes of pure aortic regurgitation in patients having isolated aortic valve replacement at a single US tertiary hospital (1993 to 2005).” Circulation (2006). PMID: 16864725 ↗

    L4OTHERCited in: Pathophysiology and Mechanism
  62. [62]

    Donnelly RT, Pinto NM, Kocolas I et al.. “The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome.” Journal of the American College of Cardiology (2012). PMID: 22789886 ↗

    L3OTHERCited in: Pathophysiology and Mechanism, Prognosis and Natural History, Special Populations and Prevention
  63. [63]

    Rochano-Ortiz A, San Sebastián-Jaraba I, Zamora C et al.. “Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response.” European heart journal (2025). PMID: 40720766 ↗

    L5OTHERCited in: Pathophysiology and Mechanism, Complications
  64. [64]

    Edouard T, Bajanca F, Flumian C et al.. “A personalized home-based exercise training program in children with Marfan and Loeys-Dietz syndromes improves aerobic exercise capacity and health-related quality of life.” Orphanet journal of rare diseases (2026). PMID: 41639855 ↗

    L4TRIAL_NONRANDOMCited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy
  65. [65]

    Krych S, Gniewek J, Jurkiewicz M et al.. “Aortopathy in Bicuspid Aortic Valve: Pathophysiology, Risk Stratification and Surgical Decision-Making-A Narrative Review.” Journal of clinical medicine (2026). PMID: 42123275 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Clinical Presentation, Severity Staging and Risk Stratification, Prognosis and Natural History
  66. [66]

    Murana G, Di Marco L, Zanella L et al.. “Bentall Procedure: A Long-term, Single Center Experience.” Seminars in thoracic and cardiovascular surgery (2025). PMID: 40614792 ↗

    L4REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Interventional and Device Therapy
  67. [67]

    Santos AR, Gutierrez RMS, Koike TE et al.. “Skeletal muscle alterations in Marfan syndrome: a systematic review.” Journal of muscle research and cell motility (2025). PMID: 40833584 ↗

    L2SR_OBSCited in: Pathophysiology and Mechanism
  68. [68]

    Shalhub S. “The aortic and arterial vulnerability spectrum: A conceptual biological framework for risk stratification and precision surgical decision-making in aortopathy and arteriopathy.” Journal of vascular surgery (2025). PMID: 40471774 ↗

    L5CASE_REPORTCited in: Pathophysiology and Mechanism, Severity Staging and Risk Stratification, History and Evolution of Treatment
  69. [69]

    Tokuno S, Takeuchi T, Nakagawa N. “Revascularization of a Saphenous Vein Graft Ostial Stenosis in a Patient With Marfan Syndrome and a Previous Bentall Procedure Who was Resuscitated From Ventricular Fibrillation.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40468704 ↗

    L4CASE_REPORTCited in: Pathophysiology and Mechanism, Interventional and Device Therapy
  70. [70]

    Wang X, Tan Q, Xu J et al.. “Genetic and molecular mechanisms of hereditary thoracic aortic aneurysm and dissection (Review).” Molecular medicine reports (2026). PMID: 42318957 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  71. [71]

    Vereckei A, Jenei Z, Vágó H et al.. “Mitral Annular Calcification, a Not So Marginal and Relatively Benign Finding as Many of Us Think: A Review.” Journal of cardiovascular development and disease (2025). PMID: 40558667 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism
  72. [72]

    Parks CA, Singh M, Wohler E et al.. “Spontaneous spinal CSF leaks: a rare variant exome sequencing study and functional analysis.” The Lancet. Neurology (2026). PMID: 42309087 ↗

    L3OTHERCited in: Pathophysiology and Mechanism
  73. [73]

    Sherrah AG, Andvik S, van der Linde D et al.. “Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan Syndrome Versus Bicuspid Aortic Valve Aneurysm.” Journal of the American College of Cardiology (2016). PMID: 26868685 ↗

    L2OTHERCited in: Clinical Presentation, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History
  74. [74]

    Korukonda S, Byers PH, Kovuri P et al.. “Genotype-aortic phenotype correlations in Marfan syndrome: a systematic review and meta-analysis of Fibrillin-1 variants.” Heart (British Cardiac Society) (2025). PMID: 41309212 ↗

    L1SR_OBSCited in: Clinical Presentation, Complications, Prognosis and Natural History
  75. [75]

    Dong ZH, Fu WG, Wang YQ et al.. “Retrograde type A aortic dissection after endovascular stent graft placement for treatment of type B dissection.” Circulation (2009). PMID: 19171859 ↗

    L4OTHERCited in: Diagnosis and Workup, Complications
  76. [76]

    Morris SA, Orbach DB, Geva T et al.. “Increased vertebral artery tortuosity index is associated with adverse outcomes in children and young adults with connective tissue disorders.” Circulation (2011). PMID: 21730308 ↗

    L2OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History
  77. [77]

    Song JM, Kim SD, Kim JH et al.. “Long-term predictors of descending aorta aneurysmal change in patients with aortic dissection.” Journal of the American College of Cardiology (2007). PMID: 17707186 ↗

    L2OTHERCited in: Diagnosis and Workup, Prognosis and Natural History
  78. [78]

    Guo S, Wang Z, Zhang N et al.. “Transcatheter closure of paravalvular leak after Bentall surgery in a Marfan patient: a rare case report.” Frontiers in cardiovascular medicine (2026). PMID: 41623879 ↗

    L4CASE_REPORTCited in: Diagnosis and Workup
  79. [79]

    Yokouchi-Konishi T, Aoki-Kamiya C, Tsuritani M et al.. “The impact of FBN1 variant types on pregnancy-related aortic dissection in women with Marfan syndrome.” International journal of cardiology (2026). PMID: 42314848 ↗

    L2OTHERCited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy
  80. [80]

    Umei M, Diller GP, Brida M et al.. “Distribution, recognition and clinical implications of syndromic conditions in adults with congenital heart disease.” Open heart (2026). PMID: 42020136 ↗

    L2OTHERCited in: Diagnosis and Workup
  81. [81]

    Bosshardt D, Merton R, Nederveen AJ et al.. “Aortic displacement and hemodynamics are abnormal in patients with Marfan syndrome: A combined four-dimensional balanced steady-state free precession and four-dimensional flow cardiac magnetic resonance study.” Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2026). PMID: 42019568 ↗

    L3OTHERCited in: Diagnosis and Workup, History and Evolution of Treatment
  82. [82]

    Narula N, Devereux RB, Ma X et al.. “Outcomes of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry.” Journal of the American Heart Association (2026). PMID: 42017320 ↗

    L2OTHERCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy
  83. [83]

    Bosshardt D, Merton R, Schrauben EM et al.. “Assessing changes in aortic motion and hemodynamics after valve-sparing aortic root surgery in Marfan syndrome using four-dimensional balanced steady-state free precession and four-dimensional flow cardiovascular magnetic resonance.” Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2026). PMID: 42001956 ↗

    L4OTHERCited in: Diagnosis and Workup, Acute and Initial Management
  84. [84]

    Bhutada S, Martin DR, Cikach F et al.. “Integrated Forward and Reverse Degradomics of Aortic Aneurysms Uncovers Their Proteolytic Landscapes and the Roles of MMP9 and Mast Cell Chymase.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41924878 ↗

    L5OTHERCited in: Diagnosis and Workup
  85. [85]

    Grewal N, Niessen HWM. “Beyond the tear: the enduring role of aortic pathology in the era of genomic medicine.” Open heart (2026). PMID: 41856676 ↗

    L5OTHERCited in: Diagnosis and Workup, Acute and Initial Management
  86. [86]

    Dwivedi KK, Wu Y, Bazzi MS et al.. “Alterations in ascending aortic hemodynamics and aortic length correlate with sex-specific thoracic aortic aneurysm dilation and lifespan in a mouse model of severe Marfan syndrome.” Computers in biology and medicine (2026). PMID: 41775185 ↗

    L5OTHERCited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy
  87. [87]

    Tournoy TK, D'hulst S, Demolder A et al.. “Telomere length in patients with Marfan Syndrome.” International journal of cardiology (2026). PMID: 41679654 ↗

    L3OTHERCited in: Diagnosis and Workup
  88. [88]

    De Backer JFA, Muino Mosquera L, Rodriguez-Palomares JF et al.. “Diagnosis and management of heritable thoracic aortic diseases.” Heart (British Cardiac Society) (2026). PMID: 41638893 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Long-term Guideline-Directed Therapy, Special Populations and Prevention
  89. [89]

    den Hartog AW, Franken R, Zwinderman AH et al.. “The risk for type B aortic dissection in Marfan syndrome.” Journal of the American College of Cardiology (2015). PMID: 25614422 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification, Acute and Initial Management, Complications
  90. [90]

    Kawashima Y, Takeda N, Omori A et al.. “Genotype-Guided Risk Stratification of Mitral Valve Surgery in Marfan Syndrome.” Journal of the American College of Cardiology (2026). PMID: 41811274 ↗

    L2OTHERCited in: Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy
  91. [91]

    Soto ME, Ochoa-Hein E, Anaya-Ayala JE et al.. “Systematic review and meta-analysis of aortic valve-sparing surgery versus replacement surgery in ascending aortic aneurysms and dissection in patients with Marfan syndrome and other genetic connective tissue disorders.” Journal of thoracic disease (2021). PMID: 34527322 ↗

    L2SR_OBSCited in: Severity Staging and Risk Stratification
  92. [92]

    Zhu QY, Lv XS, Li SM et al.. “Prognostic analysis of acute type A aortic dissection after different surgical interventions: a cohort study.” Journal of thoracic disease (2024). PMID: 39831215 ↗

    L2COHORTCited in: Severity Staging and Risk Stratification
  93. [93]

    Qiu F, Luo L, Huang J et al.. “Case Report: Improved axillary artery cannulation and extracorporeal membrane oxygenation bridging therapy for cardiogenic shock caused by Marfan syndrome combined with aortic dissection.” Frontiers in cardiovascular medicine (2026). PMID: 41908050 ↗

    L4CASE_REPORTCited in: Severity Staging and Risk Stratification, Acute and Initial Management, Interventional and Device Therapy, History and Evolution of Treatment
  94. [94]

    Pugnaloni F, De Rose DU, Digilio MC et al.. “Neonatal Marfan syndrome: a case report of a novel fibrillin 1 mutation, with genotype-phenotype correlation and brief review of the literature.” Italian journal of pediatrics (2024). PMID: 39294662 ↗

    L4CASE_REPORTCited in: Severity Staging and Risk Stratification
  95. [95]

    Wang C, Wang G, Lu W et al.. “MitraClip used for severe mitral regurgitation after surgery for type A aortic dissection combined with Marfan syndrome.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2023). PMID: 37526225 ↗

    L4CASE_REPORTCited in: Severity Staging and Risk Stratification, Interventional and Device Therapy
  96. [96]

    Kawamura I, Yamaguchi T, Yanagida H et al.. “Factors contributing to severe scoliosis after open chest surgery for congenital heart disease: a case-control analysis.” Spine deformity (2024). PMID: 39531160 ↗

    L3CASE_CONTROLCited in: Severity Staging and Risk Stratification
  97. [97]

    van Andel MM, Indrakusuma R, Jalalzadeh H et al.. “Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial.” European heart journal (2020). PMID: 32548624 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  98. [98]

    Groenink M, den Hartog AW, Franken R et al.. “Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.” European heart journal (2013). PMID: 23999449 ↗

    L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications
  99. [99]

    Pitcher A, Spata E, Emberson J et al.. “Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.” Lancet (London, England) (2022). PMID: 36049495 ↗

    L1SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications
  100. [100]

    Nataatmadja M, West J, West M. “Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm.” Circulation (2006). PMID: 16820603 ↗

    L5OTHERCited in: Acute and Initial Management, Complications
  101. [101]

    Holmes KW, Markwardt S, Eagle KA et al.. “Cardiovascular Outcomes in Aortopathy: GenTAC Registry of Genetically Triggered Aortic Aneurysms and Related Conditions.” Journal of the American College of Cardiology (2022). PMID: 35618343 ↗

    L2OTHERCited in: Acute and Initial Management, Complications
  102. [102]

    Mimoun L, Detaint D, Hamroun D et al.. “Dissection in Marfan syndrome: the importance of the descending aorta.” European heart journal (2010). PMID: 21147864 ↗

    L2OTHERCited in: Acute and Initial Management, Complications, Prognosis and Natural History
  103. [103]

    David TE, Weiss J, Runeckles K et al.. “Late adverse cardiovascular events after aortic valve-sparing operations in patients with Marfan syndrome.” The Journal of thoracic and cardiovascular surgery (2026). PMID: 42092498 ↗

    L4OTHERCited in: Acute and Initial Management
  104. [104]

    Lian T, Pai CW, Woznicki E et al.. “Nonsyndromic familial type B aortic dissection exhibits distinct clinical profiles and operative outcomes.” Journal of vascular surgery (2026). PMID: 42082039 ↗

    L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment
  105. [105]

    Zhao S, Hua X, Zhu D et al.. “SPP1high fibrogenic macrophages mediate protective fibrotic remodeling and promote vascular stability in hypertension-associated aortic dissection.” BMC medicine (2026). PMID: 41840626 ↗

    L4OTHERCited in: Acute and Initial Management
  106. [106]

    Ouzounian M, Rao V, Manlhiot C et al.. “Valve-Sparing Root Replacement Compared With Composite Valve Graft Procedures in Patients With Aortic Root Dilation.” Journal of the American College of Cardiology (2016). PMID: 27765186 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  107. [107]

    Itagaki S, Chikwe JP, Chiang YP et al.. “Long-Term Risk for Aortic Complications After Aortic Valve Replacement in Patients With Bicuspid Aortic Valve Versus Marfan Syndrome.” Journal of the American College of Cardiology (2015). PMID: 26046728 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History
  108. [108]

    McArthur M, Lee SL, Chiu MZ et al.. “Bracing for Success: Long-term Patient-reported Outcomes of Bracing Therapy for Pectus Carinatum.” The Journal of surgical research (2026). PMID: 42419066 ↗

    L4OTHERCited in: Long-term Guideline-Directed Therapy
  109. [109]

    MacCarrick G, Afifi RO, Allen R et al.. “Loeys-Dietz syndrome: 2026 updated care management primer.” Genetics in medicine : official journal of the American College of Medical Genetics (2026). PMID: 41988792 ↗

    L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy
  110. [110]

    Park I, Cho JH, Sung K et al.. “Impact of Severe Uncorrected Pectus Excavatum on Outcomes After Aortic Surgery in Marfan Syndrome.” The Annals of thoracic surgery (2026). PMID: 41966293 ↗

    L2OTHERCited in: Long-term Guideline-Directed Therapy
  111. [111]

    Xu Y, Xia YH, Bai ZM et al.. “Management strategies for acute type A aortic dissection during pregnancy: a single-center retrospective experience.” BMC pregnancy and childbirth (2026). PMID: 41673593 ↗

    L4OTHERCited in: Long-term Guideline-Directed Therapy
  112. [112]

    Allen JD, Duong BQ, Brady J et al.. “Pharmacotherapy Risks in Rare Genetic Diseases: Cross-Referencing ACMG Secondary Findings v3.2 List With Clinical Databases.” Clinical and translational science (2026). PMID: 41527333 ↗

    L5OTHERCited in: Long-term Guideline-Directed Therapy
  113. [113]

    Gaudino M, Girardi LN, Rahouma M et al.. “Editor's Choice - Aortic Re-operation After Replacement of the Proximal Aorta: A Systematic Review and Meta-Analysis.” European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery (2018). PMID: 30037741 ↗

    L2SR_OBSCited in: Interventional and Device Therapy
  114. [114]

    Burgstaller JM, Held U, Mosbahi S et al.. “A systemic review and meta-analysis: long-term results of the Bentall versus the David procedure in patients with Marfan syndrome.” European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2018). PMID: 29893811 ↗

    L2SR_OBSCited in: Interventional and Device Therapy
  115. [115]

    Van Hoof L, Lamberigts M, Noé D et al.. “Matched comparison between external aortic root support and valve-sparing root replacement.” Heart (British Cardiac Society) (2023). PMID: 36650042 ↗

    L2RCTCited in: Interventional and Device Therapy
  116. [116]

    Al-Thani H, Mekkodathil A, El-Menyar A. “Management and Outcomes of Aortic Dissection in Pregnancy with Marfan Syndrome: A Systematic Review.” Current vascular pharmacology (2020). PMID: 30963974 ↗

    L2SR_OBSCited in: Interventional and Device Therapy
  117. [117]

    Ricciardi G, Soquet J, Abou-Arab O et al.. “Heart Transplantation After Acute Aortic Dissection in an Adolescent With Marfan Syndrome.” The Annals of thoracic surgery (2021). PMID: 34560040 ↗

    L4CASE_REPORTCited in: Interventional and Device Therapy
  118. [118]

    Uchida T, Hamasaki A, Kuroda Y et al.. “Aortic Graft Dehiscence After Valve-Sparing Root Replacement.” The Annals of thoracic surgery (2019). PMID: 30794782 ↗

    L4CASE_REPORTCited in: Interventional and Device Therapy
  119. [119]

    Herrmann FEM, Schramm R, Hagl C et al.. “Aortic Root Replacement and Berlin Heart EXCOR Implantation in Marfan Syndrome.” The Annals of thoracic surgery (2018). PMID: 30266613 ↗

    L4CASE_REPORTCited in: Interventional and Device Therapy
  120. [120]

    Nabi HA, Dreher L, Bcharah H et al.. “Efficacy and safety of atrial fibrillation ablation in patients with Marfan syndrome: A multicenter analysis.” Heart rhythm O2 (2026). PMID: 42369794 ↗

    L2OTHERCited in: Interventional and Device Therapy
  121. [121]

    Maron BJ, Chaitman BR, Ackerman MJ et al.. “Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases.” Circulation (2004). PMID: 15184297 ↗

    L5GUIDELINECited in: History and Evolution of Treatment
  122. [122]

    Forteza A, Evangelista A, Sánchez V et al.. “Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial.” European heart journal (2015). PMID: 26518245 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  123. [123]

    Nicod P, Bloor C, Godfrey M et al.. “Familial aortic dissecting aneurysm.” Journal of the American College of Cardiology (1989). PMID: 2647812 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  124. [124]

    Donofrio MT, Engle MA, O'Loughlin JE et al.. “Congenital aortic regurgitation: natural history and management.” Journal of the American College of Cardiology (1992). PMID: 1634673 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  125. [125]

    Finkbohner R, Johnston D, Crawford ES et al.. “Marfan syndrome. Long-term survival and complications after aortic aneurysm repair.” Circulation (1995). PMID: 7828300 ↗

    L4OTHERCited in: History and Evolution of Treatment
  126. [126]

    Pape LA, Tsai TT, Isselbacher EM et al.. “Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD).” Circulation (2007). PMID: 17709637 ↗

    L4OTHERCited in: History and Evolution of Treatment
  127. [127]

    Yun KL, Miller DC, Fann JI et al.. “Composite valve graft versus separate aortic valve and ascending aortic replacement: is there still a role for the separate procedure?” Circulation (1997). PMID: 9386126 ↗

    L2OTHERCited in: History and Evolution of Treatment
  128. [128]

    Goldfinger JZ, Preiss LR, Devereux RB et al.. “Marfan Syndrome and Quality of Life in the GenTAC Registry.” Journal of the American College of Cardiology (2017). PMID: 28595698 ↗

    L2OTHERCited in: History and Evolution of Treatment, Complications
  129. [129]

    Silverman DI, Gray J, Roman MJ et al.. “Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival.” Journal of the American College of Cardiology (1995). PMID: 7560600 ↗

    L2OTHERCited in: History and Evolution of Treatment
  130. [130]

    Januzzi JL, Isselbacher EM, Fattori R et al.. “Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD).” Journal of the American College of Cardiology (2004). PMID: 14975480 ↗

    L4OTHERCited in: History and Evolution of Treatment
  131. [131]

    Ma Y, Zhang X, Jin L et al.. “Social Media Interventions and Postoperative Follow-Up in Congenital Ectopia Lentis: A Randomized Clinical Trial.” JAMA ophthalmology (2025). PMID: 40208617 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History
  132. [132]

    Jouini S, Milleron O, Eliahou L et al.. “Online Personal Training in Patients With Marfan Syndrome: A Randomized Controlled Study of Its Impact on Quality of Life and Physical Capacity.” Journal of the American Heart Association (2024). PMID: 39291498 ↗

    L1RCTCited in: History and Evolution of Treatment
  133. [133]

    Gott VL, Pyeritz RE, Magovern GJ et al.. “Surgical treatment of aneurysms of the ascending aorta in the Marfan syndrome. Results of composite-graft repair in 50 patients.” The New England journal of medicine (1986). PMID: 2938007 ↗

    L4OTHERCited in: History and Evolution of Treatment
  134. [134]

    Glesby MJ, Pyeritz RE. “Association of mitral valve prolapse and systemic abnormalities of connective tissue. A phenotypic continuum.” JAMA (1989). PMID: 2739055 ↗

    L4OTHERCited in: History and Evolution of Treatment
  135. [135]

    Hawass Z, Gad YZ, Ismail S et al.. “Ancestry and pathology in King Tutankhamun's family.” JAMA (2010). PMID: 20159872 ↗

    L4OTHERCited in: History and Evolution of Treatment, Prognosis and Natural History
  136. [136]

    Pfister GC, Puffer JC, Maron BJ. “Preparticipation cardiovascular screening for US collegiate student-athletes.” JAMA (Unknown). PMID: 10735397 ↗

    L4OTHERCited in: History and Evolution of Treatment
  137. [137]

    Glover DW, Maron BJ. “Profile of preparticipation cardiovascular screening for high school athletes.” JAMA (1998). PMID: 9628714 ↗

    L5OTHERCited in: History and Evolution of Treatment
  138. [138]

    Cuozzo S, Jabbour J, D'Amico C et al.. “Urgent Relining of a Fenestrated Stent-Graft for Symptomatic Type V TAAA due to Late Type IIIB and IIIC Endoleaks in a Patient With Marfan Syndrome Case Report and Literature Review.” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2025). PMID: 40580078 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  139. [139]

    Su C, Zeng L, Lu H et al.. “Case Report: A FBN1 frameshift-and-nonsense mutation and aortic dissection in Marfan syndrome.” Frontiers in cardiovascular medicine (2025). PMID: 40336639 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  140. [140]

    Darveau SC, Sylvestre G, Weingarten SJ. “Prenatal Diagnosis of Congenital Paraesophageal Hernia With Gastric Volvulus and Postnatal FBN1 Mutation Confirmation.” Prenatal diagnosis (2025). PMID: 39993998 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  141. [141]

    Caro R, Savel P, Moss PI. “Evaluation of Short and Tall Stature in Children.” American family physician (2025). PMID: 40531152 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  142. [142]

    Cai X, Chen W, Xue J et al.. “Diagnosis of congenital ectopia lentis: a case report and review of the literature.” Journal of medical case reports (2025). PMID: 40542356 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  143. [143]

    McLoughlin D, McGuinness J, Byrne J et al.. “Pravastatin reduces Marfan aortic dilation.” Circulation (2011). PMID: 21911808 ↗

    L5OTHERCited in: Complications
  144. [144]

    Pilop C, Aregger F, Gorman RC et al.. “Proteomic analysis in aortic media of patients with Marfan syndrome reveals increased activity of calpain 2 in aortic aneurysms.” Circulation (2009). PMID: 19720936 ↗

    L3OTHERCited in: Complications
  145. [145]

    Yang P, Liu H, Wang S et al.. “PIEZO1 attenuates Marfan syndrome aneurysm development through TGF-β signaling pathway inhibition via TGFBR2.” European heart journal (2025). PMID: 39585648 ↗

    L5OTHERCited in: Complications
  146. [146]

    Cohen SA, Kalavar M, Sridhar J. “Surgical approach to ocular complications of Marfan syndrome.” Current opinion in ophthalmology (2026). PMID: 41496654 ↗

    L5REVIEW_NARRATIVECited in: Complications
  147. [147]

    Nariai M, Wada-Hiraike O, Sasabuchi Y et al.. “Aortic dissection during the perinatal period in women with Marfan-related disorders: a retrospective cohort study using the Japanese Diagnosis Procedure Combination database.” The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2026). PMID: 41866242 ↗

    L2COHORTCited in: Complications, Special Populations and Prevention
  148. [148]

    Arai W, Furuya M, Nakatani Y et al.. “Pulmonary Vascular Abnormalities and Spontaneous Pneumothorax in Loeys-Dietz Syndrome.” Pathology international (2026). PMID: 41492809 ↗

    L4CASE_REPORTCited in: Complications
  149. [149]

    Elkayam U, Goland S, Pieper PG et al.. “High-Risk Cardiac Disease in Pregnancy: Part II.” Journal of the American College of Cardiology (2016). PMID: 27443948 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History, Special Populations and Prevention
  150. [150]

    Franken R, Groenink M, de Waard V et al.. “Genotype impacts survival in Marfan syndrome.” European heart journal (2016). PMID: 26787436 ↗

    L2OTHERCited in: Prognosis and Natural History
  151. [151]

    Saraber PJMH, Bica LC, Reesink KD et al.. “The clinical relevance of the decelerating effect of angiotensin receptor blockers on aortic growth in Marfan patients; a Bayesian perspective.” International journal of cardiology (2025). PMID: 40288542 ↗

    L5SR_OBSCited in: Prognosis and Natural History
  152. [152]

    Isselbacher EM, Preventza O, Hamilton Black J et al.. “2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.” The Journal of thoracic and cardiovascular surgery (2023). PMID: 37389507 ↗

    L1GUIDELINECited in: Special Populations and Prevention
  153. [153]

    Hart DA. “Regulation of Joint Tissues and Joint Function: Is There Potential for Lessons to Be Learned Regarding Regulatory Control from Joint Hypermobility Syndromes?” International journal of molecular sciences (2025). PMID: 39941023 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  154. [154]

    Warner D, Holmes KW, Afifi R et al.. “Emergency vascular surgical care in populations with unique physiologic characteristics: Pediatric, pregnant, and frail populations.” Seminars in vascular surgery (2023). PMID: 37330246 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  155. [155]

    Curtis SL, Swan L. “Aortopathy in pregnancy.” Heart (British Cardiac Society) (2022). PMID: 35144984 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention
  156. [156]

    Zeng Y, Hu Y, Jiang B et al.. “Unusual combination of acute aortic dissection, Mayer-Rokitansky-Küster-Hauser syndrome, and 46,XX gonadal dysgenesis: A case report.” Frontiers in cardiovascular medicine (2022). PMID: 36440024 ↗

    L4CASE_REPORTCited in: Special Populations and Prevention
  157. [157]

    Małek Ł, Lemańska A, Śpiewak M. “Pectus Excavatum-A Frequent but Often Neglected Entity in Sports Cardiology.” Diagnostics (Basel, Switzerland) (2025). PMID: 41374337 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Prevention

Revision History

All updates applied to this page

Loading revisions…